Vision, Inc (Redwood City, CA). The authors report receiving research funding from the Center of Community Outreach and Policy, UCLA Stein Eye Institute, University of California, Los Angeles. No other disclosures are reported.


**CORRECTION**

Error in Figure 2: In the Original Investigation titled “Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial,”1 published online May 2, 2018, the points indicating intravitreal aflibercept injection plus sham photodynamic therapy and intravitreal aflibercept injection plus active photodynamic therapy in panel A of Figure 2 were transposed. This article was corrected online.